Diagnosing steatohepatitis and predicting liver-related mortality in patients with NAFLD: Two distinct concepts
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
The diagnosis of nonalcoholic steatohepatitis (NASH) is based on both the presence of certain lesions (i.e., steatosis, inflammation, hepatocyte ballooning, and fibrosis) and the pattern of those lesions within the liver parenchyma in the absence of alcohol abuse. Over the last 2 decades, different criteria have been suggested for scoring and staging the histological lesions, and different definitions of NASH have been used in numerous NASH-related publications. The nonalcoholic fatty liver disease activity score (NAS) system, which has been proposed by the National Institute of Diabetes and Digestive and Kidney Diseases–sponsored NASH Clinical Research Network Pathology Committee, has gained enormous acceptance because of its simplicity and straightforwardness.1 The NAS system provides a numerical score for each histological lesion and allows the grading of steatosis, inflammation, and ballooning. Although fibrosis is not included in the NAS system, this system does contain a separate numerical score for staging fibrosis. Like other systems used to score liver biopsy features for other liver diseases, the NAS system was developed as a means of evaluating the changes in individual histological lesions that can occur over time either spontaneously or because of specific treatments during clinical trials.1 NAFLD, nonalcoholic fatty liver disease; NAS, nonalcoholic fatty liver disease activity score; NASH, nonalcoholic steatohepatitis In 1999, two important studies were published: Brunt et al.2 proposed a scoring system for grading the severity of NASH (mild, moderate, or severe), and Matteoni et al.3 proposed the classification of nonalcoholic fatty liver disease (NAFLD) into four subtypes based on combinations of liver lesions. Subsequently, data from several publications around the world have convincingly demonstrated that patients with confirmed NAFLD have a worse prognosis in comparison with the general population (matched by age and sex),4-7 and the prognosis of patients with NAFLD varies with the severity of the liver injury.8 The original definition proposed by the same investigators in 1999,3 which is based on steatosis plus hepatocyte ballooning, Mallory-Denk bodies, or fibrosis. The definition proposed by Younossi et al. in this publication, which is based on steatosis plus centrilobular ballooning, Mallory-Denk bodies, or fibrosis. An NAS ≥ 5.1 Brunt's definition, which is based on steatosis and lobular inflammation.2 The reported κ statistic (κ = 0.896) indicates almost perfect agreement between Younossi et al.'s current definition of NASH and the original definition; this is not surprising because the two definitions are essentially identical. The agreement between the current definition and an NAS ≥ 5 is moderate (κ = 0.511), and it remains in the moderate range even if the NAS threshold is reduced to 3. The agreement between the current definition and Brunt's definition is only fair (κ = 0.365). The agreement between an NAS ≥ 5 and Brunt's definition is less than fair with a κ value of only 0.178. Although these data are interesting, several issues that may affect their clinical relevance need to be discussed. First, the NAS system is not intended to categorize patients according to their NASH status; instead, it is meant to be used to evaluate the changes in individual histological features, as mentioned previously.1 Second, most experts in the field would agree that the presence of only steatosis and lobular inflammation in a liver biopsy sample (i.e., one of the NASH definitions used in this study) should not be called NASH, at least according to our understanding of the condition. Third, it is unfortunate that the investigators have not included in the agreement analysis another proposed definition of NASH, which separates patients into those with definitive NASH, those with borderline NASH, and those without NASH (according to a liver pathologist) and is based only on the severity and pattern of the liver injury, regardless of the NAS numerical value.1, 10 Finally, it is unclear whether the liver biopsy slides for the 257 patients were read all at once by both pathologists exclusively for this study or the scores of some biopsies were retrieved from older data sets. The second part of Younossi et al.'s study9 included 209 patients who had a median follow-up of approximately 12 years. Sixty-four of these patients (30.6%) died; 18 (8.6%) died because of liver-related causes. In adjusted multivariate Cox regression analyses, NASH according to the original definition with NAFLD subtypes3 and NASH according to the definition in this study correlated significantly with a higher liver-related mortality rate; the hazard ratios were 9.94 (95% confidence interval = 1.28-77.1, P = 0.03) and 4.43 (95% confidence interval = 0.97-20.2, P = 0.05), respectively. NASH according to the other definitions (NAS ≥ 51 and Brunt's criteria2) did not reach statistical significance. Additional multivariate Cox regr
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study
Adams, L. A., Lymp, J. F., St. Sauver, J., Sanderson, S. O., Lindor, K. D., Feldstein, A., & Angulo, P. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.04.014 · Cited by 2,890
Self-citationLong-term follow-up of patients with NAFLD and elevated liver enzymes
Ekstedt, M., Franzén, L. E., Mathiesen, U. L., Thorelius, L., Holmqvist, M., Bodemar, G., & Kechagias, S. (2006) · Hepatology · doi:10.1002/hep.21327 · Cited by 2,302
Brunt, E. M., Kleiner, D. E., Wilson, L. A., Belt, P., & Neuschwander-Tetri, B. A. (2011) · Hepatology · doi:10.1002/hep.24127 · Cited by 1,251
Cited by
Angulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
Self-citationLaBrecque, D. R., Abbas, Z., Anania, F., Ferenci, P., Khan, A. G., Goh, K.-L., Hamid, S. S., Isakov, V., Lizarzabal, M., Peñaranda, M. M., et al. (2014) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000116 · Cited by 519
NAFLD in Asia—as common and important as in the West
Farrell, G. C., Wong, V. W.-S., & Chitturi, S. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.34 · Cited by 432
NASH is an Infl ammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications
Farrell, G. C., Rooyen, D. V., Gan, L., & Chitturi, S. (2012) · Gut and Liver · doi:10.5009/gnl.2012.6.2.149 · Cited by 398
Role of cytokines and chemokines in non-alcoholic fatty liver disease
Braunersreuther, V. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i8.727 · Cited by 362
Features, Diagnosis, and Treatment of Nonalcoholic Fatty Liver Disease
Torres, D. M., Williams, C. D., & Harrison, S. A. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.03.011 · Cited by 268
Effect of resistance training on non-alcoholic fatty-liver disease a randomized-clinical trial
Zelber-Sagi, S. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i15.4382 · Cited by 152
Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride
Jendle, J., Hyötyläinen, T., Orešič, M., & Nyström, T. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01431-2 · Cited by 27
Metadata
- Authors
- Angulo, P.
- Venue
- Hepatology
- Published
- 2011-06
- Volume
- 53
- Issue
- 6
- Pages
- 1792-1794
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2012273074
- Cited by
- 58
- References
- 3
- FWCI
- 6.05
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.